Skip to main navigation Skip to search Skip to main content

Brain-derived tau for monitoring brain injury in acute ischemic stroke

  • ESCAPE-NEXT biomarker substudy investigators
  • , DEMDAS study group
  • Ludwig-Maximilians-Universität
  • University of Tubingen
  • University of Basel
  • Munich Cluster of Systems Neurology (SyNergy)
  • Sahlgrenska University Hospital/Östra
  • Charite - Universitatsmedizin Berlin
  • German Center for Mental Health (DZPG)
  • German Centre for Neurodegenerative Diseases (DZNE)
  • Otto von Guericke University Magdeburg
  • University of Bonn
  • Technical University of Munich
  • Georg August University Göttingen
  • University of British Columbia
  • University Hospital Wuerzburg
  • Sunnybrook and Women's College Health Sciences Centre
  • Hospital Altenburger Land GmbH
  • St Michael's Hospital
  • Klinikum Augsburg
  • Universitätsklinikum Carl Gustav Carus
  • University of Manitoba
  • University of Oslo
  • University of Western Ontario
  • University Witten/Herdecke
  • Ruprecht-Karls Universität Heidelberg
  • RWTH Aachen University
  • Department of Medicine
  • Cumming School of Medicine
  • NoNO Inc.
  • Hotchkiss Brain Institute

Abstract

A specific and accurate blood test for acute brain injury could help monitor infarct growth in ischemic stroke and serve as a surrogate end point in clinical trials. Using a single-molecule detection assay, we assessed plasma brain-derived tau (BD-tau), a marker selectively quantifying tau protein from the central nervous system, in a prospective cohort of 502 patients with acute ischemic stroke with serial blood sampling from admission to day 7. Higher BD-tau concentrations at admission were associated with more extensive early brain injury on computed tomography and predicted larger final infarct volumes. BD-tau increases from admission to day 2 were related to infarct growth. BD-tau concentrations rose until day 7 and were higher in patients with secondary events, including recurrent stroke. After thrombectomy, the rise of BD-tau was smaller in patients with complete versus incomplete recanalization. BD-tau outperformed other blood markers and imaging metrics in predicting 90-day functional outcome across infarct size strata and time points. In an independent multicenter prospective cohort (N = 519), BD-tau showed higher performance than magnetic resonance imaging–derived final infarct volume in predicting functional outcomes at 3, 12, and 36 months. In the biomarker substudy of a phase 3 trial assessing nerinetide in patients with ischemic stroke (N = 193), BD-tau showed predictive performance comparable to the other cohorts, mediated the relationship between recanalization and functional outcome, and showed a 49% smaller increase in the nerinetide group versus placebo. Overall, plasma BD-tau tracked ischemic brain injury over time, outperformed other biomarkers in predicting functional outcomes, and identified possible treatment responses.

Original languageEnglish
Article numbereadz1280
JournalScience Translational Medicine
Volume18
Issue number832
Pages (from-to)eadz1280
ISSN1946-6234
DOIs
Publication statusPublished - 14.01.2026

Funding

FundersFunder number
Medtronic
University of Calgary
Munich Cluster for Systems Neurology390857198
Fondation Leducq21cVd04
Corona-StiftungPJT-180434, S199/10081/2020
Bundesministerium für Forschung, Technologie und RaumfahrtlMUexcellent nFF-1507
Friedrich‐Baur‐Stiftung2 en343/16-1
Stiftung zur Erforschung der Vaskulären Demenz22cVd01
Deutsche Forschungsgemeinschaft540798028
Ludwig-Maximilians-Universität1216/1176

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    DFG Research Classification Scheme

    • 2.23-07 Clinical Neurology, Neurosurgery and Neuroradiology

    Fingerprint

    Dive into the research topics of 'Brain-derived tau for monitoring brain injury in acute ischemic stroke'. Together they form a unique fingerprint.

    Cite this